Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year
Veristat , a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. Since its first appearance on the list in 2015, Veristat has accelerated its growth in size, geographic reach and ability to successfully guide clinical trials through the development process to regulatory approval.
“Veristat’s ability to achieve this national recognition and to remain on this list for 4 consecutive years highlights our sustainability, innovation and unfaltering commitment to consistently delivering the highest quality clinical development and regulatory submission services to our clients,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “The meaningful impact that our teams provide to our clients and to lives of the patients their programs benefit is astounding. In 2018, our teams supported five regulatory submissions that were submitted to the US Food & Drug Administration (FDA) and Health Canada. Four of the submission projects which we previously supported received approval this year.”
Veristat strives to work collaboratively with biotechnology and pharmaceutical companies throughout the entire clinical development life cycle: from trial design all the way to regulatory approval. The Company plans to embark on an even more aggressive growth strategy in the coming year to further improve and expand our capabilities into new services offerings and geographies to pro-actively address the needs of our growing client base.
Inc. Magazine has been ranking the top 5000 fastest-growing private companies since 1982. Earning a spot on this list is a milestone achievement. The list represents risk-takers and entrepreneurs that build something great from the ground up, a feat many cannot say they have accomplished. According to INC.com, this year’s fastest-growing companies in America are a force, notching collective revenue of more than $206.2 billion in 2017 and three-year revenue growth rates that reach 75,661 percent. To learn more, view the 2018 Inc. 5000 List .
Veristat is a clinical research partner focused on supporting biopharmaceutical firms as they advance their therapies through the clinical development and regulatory submission process. Our work delivers meaningful clinical impact and our regulatory submission expertise is unrivaled in our industry. Veristat teams have supported over 70 regulatory submission projects that have resulted in more than 40 submission approvals to date from various regulatory agencies around the world. We work collaboratively with clients to create a personalized project team of collaborative problem-solvers based on their therapy area and clinical development needs. Veristat aims is to propel even the most complex submissions to successful regulatory conclusions so that new therapies become available to improve and save lives. For more information on our impactful strategic consulting, data analysis, clinical trial management or regulatory submission expertise, visit www.veristat.com .
Gillian Dellacioppa, 508-306-6336
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-ARENSIS/SCHNEIDER25.9.2018 15:02 | pressemeddelelse
Arensis and Schneider Electric Launch Smart Microgrid Partnership and Development of ENTRADE IO Blockchain Technology
RI-CLARKE-VALVE25.9.2018 15:02 | pressemeddelelse
Clarke Valve Closes $5.5 Million Venture Funding Round Led by OGCI Climate Investments
CA-ANALOGIX25.9.2018 15:02 | pressemeddelelse
Analogix Introduces Industry’s Lowest Power eDP TCON with In-Cell Touch for Latest Generation Notebooks
MA-TAKEDA-PHARMACEUTICAL25.9.2018 14:34 | pressemeddelelse
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC
SOFTOMOTIVE25.9.2018 14:17 | pressemeddelelse
Softomotive and Enate Partner to Help Clients Orchestrate Workflows across Their RPA Ecosystem
CA-SCIENTIST.COM25.9.2018 14:08 | pressemeddelelse
Scientist.com Adds Experienced Drug Hunter Mark Herbert to Management Team
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum